Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 7/20 | 0.67 |
| ▸ | GSK3B | P49841 | 7/20 | 0.67 |
| ▸ | AURKA | O14965 | 4/20 | 0.67 |
| ▸ | EIF2AK4 | Q9P2K8 | 3/20 | 0.47 |
| ▸ | MAPK6 | Q16659 | 5/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | WEE1 | P30291 | 4/20 | 0.41 |
| ▸ | SRC | P12931 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16245611 | 0.99 | GSK3A (0.66) | GSK3AGSK3BAURKAEIF2AK4MAPK6 | |
| SCHEMBL16264840 | 0.97 | GSK3A (0.67) | GSK3AGSK3BAURKAEIF2AK4MAPK6 | |
| SCHEMBL16264862 | 0.93 | GSK3A (0.65) | GSK3AGSK3BAURKAEIF2AK4MAPK6 | |
| SCHEMBL17821180 | 0.90 | GSK3A (0.67) | GSK3AGSK3BAURKAEIF2AK4MAPK6 | |
| SCHEMBL16245550 | 0.85 | GSK3A (0.59) | GSK3AGSK3BAURKAEIF2AK4MAPK6 | |
| SCHEMBL16245597 | 0.84 | EIF2AK4 (0.60) | GSK3AGSK3BAURKAEIF2AK4MAPK6 | |
| Hydrochloric Acid SCHEMBL17821184 | 0.84 | EIF2AK4 (0.59) | GSK3AGSK3BAURKAEIF2AK4MAPK6 | |
| SCHEMBL16245670 | 0.82 | GSK3A (0.60) | GSK3AGSK3BAURKAEIF2AK4MAPK6 | |
| SCHEMBL16245529 | 0.82 | GSK3A (0.59) | GSK3AGSK3BAURKAEIF2AK4MAPK6 | |
| SCHEMBL16245546 | 0.82 | RPS6KA3 (0.57) | GSK3AGSK3BAURKARPS6KA3WEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9861635-B2 | Macrocycles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| EP-2994471-B1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | EIF2AK4, CDK2, CDK1 | GSK3A 523/4885GSK3B 482/4885AURKA 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.